Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Return on Sales (2016 - 2025)

Ocular Therapeutix has reported Return on Sales over the past 13 years, most recently at 4.92% for Q4 2025.

  • Quarterly results put Return on Sales at 4.92% for Q4 2025, down 206.0% from a year ago — trailing twelve months through Dec 2025 was 5.07% (down 248.0% YoY), and the annual figure for FY2025 was 5.07%, down 248.0%.
  • Return on Sales for Q4 2025 was 4.92% at Ocular Therapeutix, down from 4.67% in the prior quarter.
  • Over the last five years, Return on Sales for OCUL hit a ceiling of 1.42% in Q3 2023 and a floor of 5.9% in Q1 2025.
  • Median Return on Sales over the past 5 years was 1.9% (2021), compared with a mean of 2.59%.
  • Biggest five-year swings in Return on Sales: surged 1060bps in 2021 and later plummeted -375bps in 2025.
  • Ocular Therapeutix's Return on Sales stood at 1.6% in 2021, then rose by 8bps to 1.48% in 2022, then fell by -4bps to 1.54% in 2023, then tumbled by -87bps to 2.87% in 2024, then tumbled by -72bps to 4.92% in 2025.
  • The last three reported values for Return on Sales were 4.92% (Q4 2025), 4.67% (Q3 2025), and 4.99% (Q2 2025) per Business Quant data.